CUMYL-FUBINACA

CUMYL-FUBINACA (SGT-149) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist, with an EC50 of 1.8nM for human CB1 receptors and 23.7nM for human CB2 receptors, giving it around 13x selectivity for CB1.[1][2][3][4] It has been sold online as a designer drug.[5]

CUMYL-FUBINACA
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class B
Identifiers
PubChem CID
Chemical and physical data
FormulaC24H22FN3O
Molar mass387.458 g·mol−1
3D model (JSmol)

See also

References
  1. Bowden; et al. (11 April 2013). "Patent WO 2014167530 - Cannabinoid compounds". New Zealand Patent application 623626.
  2. Longworth M, Banister SD, Boyd R, Kevin RC, Connor M, McGregor IS, Kassiou M (October 2017). "Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues". ACS Chemical Neuroscience. 8 (10): 2159–2167. doi:10.1021/acschemneuro.7b00267. PMID 28792725.
  3. Banister SD, Connor M. "The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution". Handbook of Experimental Pharmacology. 252: 191–226. doi:10.1007/164_2018_144. PMID 30105473.
  4. Krishna Kumar K, Shalev-Benami M, Robertson MJ, Hu H, Banister SD, Hollingsworth SA, et al. (January 2019). "Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex". Cell. 176 (3): 448–458.e12. doi:10.1016/j.cell.2018.11.040. PMID 30639101.
  5. Thornton SL, Darracq MA, Gugelmann HM Armenian P. Surface internet marketplace presence and availability of NPS sold as research chemicals: a snapshot study. Toxicology Communications 2019; 3(1): 67-74. doi:10.1080/24734306.2019.1648067
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.